Hao-Fountain syndrome due to USP7 mutation

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:643538OMIM:616863
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Hao-Fountain syndrome (also known as Hao-Fountain syndrome due to USP7 mutation, or USP7-related neurodevelopmental disorder) is a rare genetic condition caused by heterozygous loss-of-function mutations or deletions in the USP7 gene (ubiquitin-specific peptidase 7) located on chromosome 16p13.2. USP7 encodes a deubiquitinating enzyme involved in multiple cellular pathways, including regulation of the tumor suppressor p53 and epigenetic modification through interaction with the Polycomb repressive complex. Loss of USP7 function disrupts normal neurodevelopment and multiple organ systems. The syndrome is characterized primarily by intellectual disability and developmental delay of variable severity, speech and language difficulties, and behavioral abnormalities including features of autism spectrum disorder, anxiety, and attention deficit. Affected individuals frequently exhibit hypotonia (low muscle tone), feeding difficulties in infancy, and seizures. Additional features may include hypogonadism, cryptorchidism in males, eye abnormalities, and nonspecific dysmorphic facial features such as a broad forehead, widely spaced eyes, and a thin upper lip. Some patients also demonstrate abnormalities in brain MRI imaging, including white matter changes. There is currently no cure or targeted therapy for Hao-Fountain syndrome. Management is supportive and multidisciplinary, focusing on early intervention services including speech therapy, occupational therapy, physical therapy, and behavioral support. Seizures are managed with standard antiepileptic medications. Endocrine abnormalities such as hypogonadism may require hormonal treatment. Regular developmental assessments and monitoring by a team including neurologists, endocrinologists, and developmental pediatricians are recommended. Research into the molecular mechanisms of USP7 dysfunction is ongoing and may eventually inform more targeted therapeutic approaches.

Also known as:

Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Infantile

Begins in infancy, roughly 1 month to 2 years old

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Hao-Fountain syndrome due to USP7 mutation.

View clinical trials →

No actively recruiting trials found for Hao-Fountain syndrome due to USP7 mutation at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Hao-Fountain syndrome due to USP7 mutation community →

No specialists are currently listed for Hao-Fountain syndrome due to USP7 mutation.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Hao-Fountain syndrome due to USP7 mutation.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Hao-Fountain syndrome due to USP7 mutationForum →

No community posts yet. Be the first to share your experience with Hao-Fountain syndrome due to USP7 mutation.

Start the conversation →

Latest news about Hao-Fountain syndrome due to USP7 mutation

No recent news articles for Hao-Fountain syndrome due to USP7 mutation.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Hao-Fountain syndrome due to USP7 mutation

What is Hao-Fountain syndrome due to USP7 mutation?

Hao-Fountain syndrome (also known as Hao-Fountain syndrome due to USP7 mutation, or USP7-related neurodevelopmental disorder) is a rare genetic condition caused by heterozygous loss-of-function mutations or deletions in the USP7 gene (ubiquitin-specific peptidase 7) located on chromosome 16p13.2. USP7 encodes a deubiquitinating enzyme involved in multiple cellular pathways, including regulation of the tumor suppressor p53 and epigenetic modification through interaction with the Polycomb repressive complex. Loss of USP7 function disrupts normal neurodevelopment and multiple organ systems. The

How is Hao-Fountain syndrome due to USP7 mutation inherited?

Hao-Fountain syndrome due to USP7 mutation follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Hao-Fountain syndrome due to USP7 mutation typically begin?

Typical onset of Hao-Fountain syndrome due to USP7 mutation is infantile. Age of onset can vary across affected individuals.